Caffeine Therapy for Apnea of Prematurity
Top Cited Papers
- 18 May 2006
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 354 (20) , 2112-2121
- https://doi.org/10.1056/nejmoa054065
Abstract
Methylxanthines reduce the frequency of apnea of prematurity and the need for mechanical ventilation during the first seven days of therapy. It is uncertain whether methylxanthines have other short- and long-term benefits or risks in infants with very low birth weight.Keywords
This publication has 26 references indexed in Scilit:
- Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) TrialNeonatology, 2005
- Impact of a Physiologic Definition on Bronchopulmonary Dysplasia RatesPediatrics, 2004
- Apnoea of prematurityPaediatric Respiratory Reviews, 2004
- Preterm outcomes research: A critical component of neonatal intensive careMental Retardation and Developmental Disabilities Research Reviews, 2002
- A New and Improved Population-Based Canadian Reference for Birth Weight for Gestational AgePediatrics, 2001
- The Role and Regulation of Adenosine in the Central Nervous SystemAnnual Review of Neuroscience, 2001
- Metabolic and respiratory effects of theophylline in the preterm infantArchives of Disease in Childhood: Fetal & Neonatal, 2000
- Methylxanthine therapy in premature infants: Sound practice, disaster, or fruitless byway?The Journal of Pediatrics, 1999
- Adenosine, Adenosine Receptors and the Actions of Caffeine *Basic & Clinical Pharmacology & Toxicology, 1995
- Aminophylline Increases Cerebral Metabolic Rate and Decreases Anoxic Survival in Young MiceScience, 1978